Industry perspectives, manufacturing excellence highlights, and our latest corporate announcements.
India faces a mounting cardiovascular crisis with over 220 million hypertensive adults. Discover how the pharmaceutical industry is responding to this growing public health challenge.
India is home to 101 million people with Type 2 Diabetes. We explore the evolving treatment landscape, combination therapies, and how branded generics support glycaemic control.
Antimicrobial resistance threatens India's healthcare future. We examine how responsible antibiotic marketing and quality branded generics support stewardship efforts.
India's nutraceuticals market is booming as chronic disease burden rises. Explore how evidence-backed supplements are becoming mainstream in clinical practice.
The Indian pharmaceutical supply chain is complex. Learn how Supracyn Pharma partners with C&F agents and distributors to ensure reliable product availability across India.
WHO-GMP certification is more than a regulatory checkbox. We explain what it means, how Indian manufacturers earn it, and why it should matter to every prescriber.
